trending Market Intelligence /marketintelligence/en/news-insights/trending/0oVaxqZENzemYnDOVq4erQ2 content esgSubNav
In This List

ATyr Pharma chief business officer to depart

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ATyr Pharma chief business officer to depart

ATyr Pharma Inc. said its chief business officer, Sanuj Ravindran, will leave the company.

Ravindran will be employed until Dec. 31. He will transition from being the chief business officer of the company to an advisory role.

Meanwhile, Mark Goldberg resigned from the board due to other commitments. Goldberg had served as a director since 2015.